ClinicalTrials.gg
RecruitingNCT07860528PROSCATEUpdated Oct 9, 2026

Study on Prostate Salvage Using High-dose-rate Brachytherapy

An observational study in Prostate Cancer, Locally Recurrent Cancer and Biochemically Recurrent Prostate Carcinoma, sponsored by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic. Recruiting at 10 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 9, 2026Study documents postedTitle changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
63
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 312 studies in Prostatic Neoplasms with a site in Spain — 72 open to participants now, 126 under way, 45 of them phase 3. Prostatic Neoplasms · Spain.

Planned enrollment
45th of 51
63 · median 470
Started
2026
with 13 others
Observational
51 of 312
15 open now
Primary completion
2032-01
later than 120 of 125 live
Registered
310th of 312
by date

Among the 312 studies in Prostatic Neoplasms with a site in Spain, this one is the 45th largest by planned enrollment of the 51 observational ones that give a count, is one of 14 that started in 2026, is one of 51 observational ones, reaches primary completion later than 120 of the 125 other live ones, and was the 310th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

72 of the 312 studies in Prostatic Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Prostatic Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

A prospective, observational, multicenter study analyzing salvage treatment for prostate cancer-diagnosed via next-generation imaging (choline positron emission tomography (PET)/prostate-specific membrane antigen (PSMA) PET and magnetic resonance imaging (MRI)) and positive biopsy-using two fractions of high-dose-rate (HDR) brachytherapy.

Read the detailed description

The objectives of this prospective, multicenter study are:

  • Primary:

    1. Biochemical relapse-free survival, defined as the time to biochemical relapse (nadir plus 2 ng/mL - Phoenix criteria).

  • Secondary:

    1. Local relapse-free survival, defined as the time from treatment to local relapse confirmed by imaging (choline PET/MRI).
    2. Analysis of acute and chronic toxicity (Common Terminology Criteria for Adverse Events [CTCAE] version 5).
    3. Assessment of patient quality of life before and after treatment to analyze the impact of local re-irradiation on daily life using the following questionnaires: International Prostate Symptom Score (IPSS), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Prostate Module (EORTC QLQ-PR25).

Primary outcome measure: Biochemical relapse-free survival, and analysis of toxicity and quality of life in patients treated with salvage brachytherapy following radical treatment.

Study population, total number of subjects, and duration: Patients who received radical-intent radiotherapy as their initial treatment (brachytherapy alone, external beam radiotherapy, or external beam radiotherapy plus a brachytherapy boost) and were diagnosed with local recurrence via next-generation imaging techniques (choline PET/PSMA PET) and prior biopsy; these patients are scheduled to undergo salvage brachytherapy as part of routine clinical practice. A calculated sample size of 63 patients will be reached over a 2-year recruitment period. Follow-up will be conducted according to standard clinical practice every 6 months for the 4-year duration of the study.

03

Conditions studied

  • Prostate Cancer
  • Locally Recurrent Cancer
  • Biochemically Recurrent Prostate Carcinoma
  • Toxicity Radiation
  • Quality of Life

Keywords

  • Prostate cancer
  • Salvage brachytherapy
  • Local recurrence
  • Reirradiation
  • Biochemical relapse-free survival
  • Local recurrence-free survival
  • Biochemical recurrence
  • Acute and chronic toxicity
  • Quality of life
  • Choline PET; PSMA PET
  • MRI
  • Prostate biopsy
  • External beam radiotherapy
  • Brachytherapy boost
  • Salvage treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients treated with radical-intent radiotherapy as their primary treatment (brachytherapy alone, external beam radiotherapy, or external beam radiotherapy plus a brachytherapy boost) who have been diagnosed with local recurrence via next-generation imaging techniques (Choline PET or PSMA PET) and prior biopsy, and who are to undergo salvage brachytherapy as part of routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 18 years.
  • Patients diagnosed with local recurrence confirmed by next-generation imaging and a positive .
  • Hormone-sensitive patient.
  • Patients whose initial treatment consisted of brachytherapy alone, external beam radiotherapy, or external beam radiotherapy with a prostate brachytherapy boost.

Exclusion criteria

Exclusion Criteria:

  • disease.
  • Castration-resistant prostate cancer, defined according to EAU (European Association of Urology) guidelines: A patient who progresses despite maintaining testosterone levels within the castration range (testosterone \<50 ng/dL or \<1.7 nmol/L) and presents with at least one of the following factors: Three consecutive rises in PSA (Prostate-Specific Antigen) levels, measured one week apart, representing two increases of 50% above the nadir, with a PSA level >2; PSA progression despite successive hormonal manipulations; Progression of bone lesions: progression or appearance of two or more bone lesions, or soft-tissue progression according to (RECIST criteria).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
63 participants (estimated)
Target follow-up
4 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Biochemical relapse-free survival

    Time from salvage brachytherapy to biochemical recurrence of prostate cancer, defined according to the Phoenix definition as a rise in prostate-specific antigen (PSA) of ≥2 ng/mL above the post-treatment PSA nadir. Patients without biochemical recurrence will be censored at the date of their last available PSA assessment or at the end of the study follow-up. PSA measurements will be obtained at 1 month after treatment and subsequently every 6 months through 48 months.

    Time frame: From the date of salvage brachytherapy to 48 months after treatment

Secondary outcomes

  1. Baseline Characteristics

    Initial disease characteristics: Initial PSA, Gleason/Grade Group, Stage Biopsy characteristics, Initial imaging, Initial treatment. Disease characteristics at recurrence: PSA at recurrence, prostate-specific antigen doubling time (PSADT), Location of recurrence, Recurrence biopsy, Urinary symptoms, Imaging findings

    Time frame: Baseline, Day 0

  2. Incidence of Late and Chronic Treatment-Related Toxicity

    Incidence and severity of late and chronic treatment-related toxicity following salvage brachytherapy, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Toxicities will include genitourinary and gastrointestinal toxicities and other treatment-related adverse events identified during follow-up.

    Time frame: From 1 month after salvage brachytherapy to 48 months after treatment

  3. Local Relapse-Free Survival

    Time from salvage brachytherapy to radiologically confirmed local recurrence of prostate cancer. Local recurrence will be assessed using imaging techniques, including prostate MRI, choline PET, and/or PSMA PET, according to routine clinical practice. Patients without radiologically confirmed local recurrence will be censored at the date of their last available imaging assessment or at the end of the study follow-up.

    Time frame: From the date of salvage brachytherapy to 48 months after treatment

  4. Incidence of Acute Treatment-Related Toxicity

    Incidence and severity of acute treatment-related toxicity following salvage brachytherapy, assessed according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Acute toxicity will include genitourinary and gastrointestinal toxicities and other treatment-related adverse events occurring during the acute post-treatment period.

    Time frame: From the date of salvage brachytherapy to 1 month after treatment

  5. Change in International Prostate Symptom Score (IPSS) From Baseline

    Change in urinary symptoms assessed using the International Prostate Symptom Score (IPSS). The IPSS will be assessed before salvage brachytherapy and during follow-up every 6 months. The change from baseline will be evaluated over the study follow-up period.

    Time frame: Baseline and every 6 months after salvage brachytherapy through 48 months

  6. Change in Prostate Cancer-Specific Quality of Life (FACT-P) From Baseline

    Change in health-related quality of life assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. The FACT-P is a 39-item questionnaire assessing health-related quality of life in patients with prostate cancer. The total score ranges from 0 to 156, with higher scores indicating better health-related quality of life. The questionnaire will be administered before salvage brachytherapy and during follow-up every 6 months. Changes from baseline in the FACT-P total score will be evaluated throughout the study follow-up period.

    Time frame: Baseline and every 6 months after salvage brachytherapy through 48 months

  7. Change in Prostate Cancer-Specific Quality of Life (EORTC QLQ-PR25) From Baseline

    Change in prostate cancer-specific health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Prostate Module (EORTC QLQ-PR25). The EORTC QLQ-PR25 consists of 25 items scored on a 0 to 100 scale after linear transformation. Higher scores indicate greater symptom burden for symptom scales and higher levels of functioning or activity for the sexual activity/function scales. The questionnaire will be administered before salvage brachytherapy and during follow-up every 6 months. Changes from baseline in the EORTC QLQ-PR25 scores will be evaluated throughout the study follow-up period..

    Time frame: Baseline and every 6 months after salvage brachytherapy through 48 months

07

Study locations

8 of 10 sites recruiting
  • Hospital HCB Benidorm
    Benidorm, Alicante 03501, Spain
    Recruiting
  • Instituto Catalán de Oncología L'Hospitalet
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
    Recruiting
    • Ana Soledad García Blanco, MD · Contactanasoledad.garcia@scsalud.es · 942 20 25 20
    • Ana Soledad García Blanco, MD · Principal investigator
  • Hospital Universitario Reina Sofía
    Córdoba, Córdoba 14004, Spain
    Recruiting
  • Instituto Oncológico de San Sebastián (Onkologikoa)
    San Sebastián, Guipuzcoa 20014, Spain
    Not yet recruiting
    • Alai Goñi Ramírez, MD · Contactagoni@onkologikoa.org · 943 32 80 00
    • Alai Goñi Ramírez, MD · Principal investigator
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid 28034, Spain
    Recruiting
    • María Teresa Muñoz Migueláñez, MD · Contactmmmiguelanez@salud.madrid.org · 91 336 84 34
    • María Teresa Muñoz Migueláñez, MD · Principal investigator
  • Hospital Universitario de Navarra
    Pamplona, Navarre 31008, Spain
    Recruiting
  • Hospital Meixoeiro
    Vigo, Pontevedra 36312, Spain
    Recruiting
  • Hospital Universitario y Politécnico La Fe
    Valencia, Valencia 46026, Spain
    Recruiting
    • Francisco Javier Celada Álvarez, MD · Contactcelada_fra@gva.es · 961 24 40 00
    • Francisco Javier Celada Álvarez, MD · Principal investigator
  • Hospital Universitario de Cruces
    Barakaldo, Vizcaya 48903, Spain
    Not yet recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jan 2032, 70 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 70 months is close to that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Mar 11, 2026
Primary completionEst.
Jan 31, 2032
CompletionEst.
Apr 30, 2032
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
3 description edited
What changed in the outcomes
  • DescriptionBaseline Characteristics: how it is measured was reworded
  • DescriptionChange in Prostate Cancer-Specific Quality of Life (EORTC QLQ-PR25) From Baseline: how it is measured was reworded
  • DescriptionChange in Prostate Cancer-Specific Quality of Life (FACT-P) From Baseline: how it is measured was reworded
Oct 9, 2026
Title
Multicenter Prospective Observational Study on Prostate Salvage Using High-dose-rate Brachytherapy.
Oct 9, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 9, 2026
    Secondary outcomes 3 description edited
    What changed in the outcomes
    • DescriptionBaseline Characteristics: how it is measured was reworded
    • DescriptionChange in Prostate Cancer-Specific Quality of Life (EORTC QLQ-PR25) From Baseline: how it is measured was reworded
    • DescriptionChange in Prostate Cancer-Specific Quality of Life (FACT-P) From Baseline: how it is measured was reworded
    Title Multicenter Prospective Observational Study on Prostate Salvage Using High-dose-rate Brachytherapy.
    + 2 other changes: verification date and description
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860528
Lead sponsor
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Mar 11, 2026
Primary completion
Jan 31, 2032 (estimated)
Completion
Apr 30, 2032 (estimated)
Last update
Oct 9, 2026

Study contacts

Patricia Willisch Santamaría, MD PhD
Contact
patricia.willisch.santamaria@sergas.es
986 811 714
Pablo Raña Díez
Contact
investigacion@seor.es
914009600
Patricia Willisch Santamaría, MD PhD
study director · Galicia Sur Health Research Institute
Pablo Raña Díez
study chair · Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion